Inhibition of type 1 diabetic hyperalgesia in streptozotocin-induced wistar versus spontaneous gene-prone BB/Worchester rats: Efficacy of a selective bradykinin B1 receptor antagonist

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 9, 2005, Pages 782-789

  Gabra, Bichoy H ^a,b   Benrezzak, Ouhida ^b   Pheng, Leng Hong ^b   Duta, Dana ^b   Daull, Philippe ^b,c   Sirois, Pierre ^a,b   Nantel, François ^b   Battistini, Bruno ^b,c  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b IPS Pharma Inc   (Canada)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

BB Wor rats; Bradykinin B1 receptor; Hyperalgesia; Streptozotocin; Type 1 diabetes

Indexed keywords

BRADYKININ B1 RECEPTOR ANTAGONIST; R 954; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ANIMAL MODEL; ARTICLE; DIABETIC NEUROPATHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; HOT PLATE TEST; HYPERALGESIA; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NOCICEPTION; NONHUMAN; PAINFUL DIABETIC NEUROPATHY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RAT STRAIN; REACTION TIME; RECEPTOR BLOCKING; SPONTANEOUS BIOBREEDING WORCHESTER DIABETIC PRONE RAT; STREPTOZOCIN DIABETES; THERMAL HYPERALGESIA;

EID: 24644473528     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000178448.79713.5f     Document Type: Article

References (60)

1. Steil CF. Diabetes mellitus. In: Diprio JT, Talbert RL, Yee GC, Matzke GR, Weels BG, Posey LM, eds. Pharmacotherapy: A Pathophysiological Approach. Stamford: Appleton and Lange, 1999:1219-43
2. Said G. Diabetic neuropathy: An update. J Neurol 1996;243:431-40
3. Singleton JR, Smith AG. Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001;24:1448-53
4. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: Effects of insulin, aldose reductase inhibition and lidocaine. Pain 1996;68:293-99
5. Backonja MM, Serra J. Pharmacologic management part 1: Better-studied neuropathic pain diseases. Pain Med 2004;5:S28-47
6. Hanninen A, Hamilton-Williams E, Kurts C. Development of new strategies to prevent type 1 diabetes: The role of animal models. Ann Med 2003;35:546-63
7. Courteix C, Eschalier A, Lavarenne J. Streptozotocin induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 1993;53:81-8
8. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International Union of Pharmacology. XLV Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005;57:27-7
9. Khan GM, Chen SR, Pan HL. Role of primary afferent nerves in allodynia caused by diabetic neuropathy in rats. Neuroscience 2002;114:291-99
10. Chen SR, Pan HL. Hypersensitivity of spinothalamic tract neurons associated with diabetic neuropathic pain in rats. J Neurophysiol 2002;87: 2726-33
11. Fox A, Eastwood C, Gentry C, Manning D, Urban L. Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. Pain 1999;81:307-16
12. Dobretsov M, Hastings SL, Romanovsky D, Stimers J, Zhang JM. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003;960:174-83
13. Joseph EK, Levine JD. Sexual dimorphism in the contribution of protein kinase C isoforms to nociception in the streptozotocin diabetic rat. Neuroscience 2003;120:907-13
14. Villetti G, Bergamaschi M, Bassani F, et al. Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-indanyl-glycinamide hydrochloride in experimental models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:804-14
15. Aley KO, Levine JD. Rapid onset pain induced by intravenous streptozotocin in the rat. J Pain 2001;2:146-50
16. Cameron NE, Jack AM, Cotter MA. Effect of alpha-lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001;31:125-35
17. Freshwater JD, Svensson CI, Malmberg AB, Calcutt NA. Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 2002;51:2249-55
18. Like AA, Guberski DL, Butler L. Diabetic BioBreeding/Worcester (BB/Wor) rats need not be lymphopenic. J Immunol 1986;136:3254-58
19. Parfrey NA, Prud'homme GJ, Colle E, et al. Immunologic and genetic studies of diabetes in the BB rat. Crit Rev Immunol 1989;9:45-6
20. Colle E, Guttmann RD, Seemayer T. Spontaneous diabetes mellitus syndrome in the rat. Association with the major histocompatibility complex. J Exp Med 1981;154:1237-42
21. Nakhooda AF, Like AA, Chappel CI, Murray FT, Marliss EB. The spontaneously diabetic Wistar rat. Metabolic and morphologic studies. Diabetes 1977;26:100-12
22. Logothetopoulos J, Valiquette N, Madura E, Cvet D. The onset and progression of pancreatic insulitis in the overt, spontaneously diabetic, young adult BB rat studied by pancreatic biopsy. Diabetes 1984;33:33-6
23. Zhang W, Slusher B, Murakawa Y, et al. GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J Neurol Sci 2002;194:21-8
24. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004;287:E497-505
25. 1 receptors for kinins. Pharmacol Rev 1998;50:357-86
26. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001;429:161-76
27. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998;55:1139-49
28. Yerneni KK, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia- induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999;48:855-64
29. 2 kinin receptor antagonists in diabetic mice. Can J Physiol Pharmacol 1996;74:586-89
30. Zuccollo A, Navarro M, Frontera M, Cueva F, Carattino M, Catanzaro O. The involvement of kallikrein-kinin system in diabetes type 1 (insulitis). Immunopharamacology 1999;45:69-74
31. Simard B, Gabra BH, Sirois P. Inhibitory effect of a novel bradykinin B, receptor antagonist, R-954, on enhanced vascular permeability in type 1 diabetic mice. Can J Physiol Pharmacol 2002;80:1203-7
32. Lawson SR, Gabra BH, Guérin B, et al. Enhanced dermal and retinal vascular permeability in streptozotocin-induced type 1 diabetes in Wistar rats: Blockade with a selective bradykinin B, receptor antagonist. Regul Pept 2005;124:221-4
33. Gabra BH, Sirois P. Role of kinin B, receptors in diabetes-induced hyperalgesia in streptozotocin-treated mice. Eur J Pharmacol 2002;457: 115-24
34. 1 receptor antagonists inhibit diabetes-mediated hyperalgesia in mice. Neuropeptides 2003;37:36-44
35. Gabra BH, Sirois P. Beneficial effect of chronic treatment with the selective bradykinin BI receptor antagonists, R-715 and R-954, in attenuating streptozotocin-diabetic thermal hyperalgesia in mice. Peptides 2003; 24:1131-39
36. 1 receptor antagonists with multi-enzymatic resistance properties. Can J Physiol Pharmacol 2002;80:287-92
37. Li XB, Scott FW, Park YH, Yoon JW. Low incidence of autoimmune type I diabetes in BB rats fed a hydrolysed casein-based diet associated with early inhibition of non-macrophage-dependent hyperexpression of MHC class 1 molecules on beta cells. Diabetologia 1995;38:1138-47
38. Chakir M, Plante GE. Endothelial dysfunction in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1996;54:45-51
39. Jacob RJ, Weber AB, Dziura J, Morgen J, Sherwin RS. Brainstem dysfunction is provoked by a less pronounced hypoglycemic stimulus in diabetic BB rats. Diabetes 1995;44:900-5
40. 1 receptor. Eur J Pharmacol 2005; 514:61-7
41. Calcutt NA. Experimental models of painful diabetic neuropathy. J Neurol Sci 2004;220:137-39
42. Eddy NP, Leimbach D. Synthetic analgesics (II), dithienylbutenyl and dithienylbutylamines. J Pharmacol Exp Ther 1953;107:385-89
43. Hartley HO. The modified Gauss-Newton method for the fitting of nonlinear regression functions by least squares. Technometrics 1961;3: 269-80
44. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.
45. Wuarin-Bierman L, Zahnd GR, Kaufmann F, Burcklen L, Adler J. Hyperalgesia in spontaneous and experimental animal models of diabetic neuropathy. Diabetologia 1987;30:653-58
46. Gabra BH, Merino VF, Bader M, Pesquero JB, Sirois P. Absence of diabetic hyperalgesia in bradykinin B, receptor-knockout mice. Regul Pept 2005;127:245-48
47. 2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level. Neuropharmacology 2002;43:1188-97
48. Pheng LH, Nguyen-Le XK, Nsa Allogho S, Gobeil F, Regoli D. Kinin receptors in the diabetic mouse. Can J Physiol Pharmacol 1997;75:609-11
49. 2 receptor agonists in the spinal cord of streptozotocin-diabetic rats. Br J Pharmacol 2000;130: 375-85
50. 1 receptors in streptozotocin diabetic rats: Possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. Can J Physiol Pharmacol 2002;80:328-33
51. 1 receptors in vivo during antigen arthritis. Agents Actions 1991;34:191-93
52. 1-receptors and altered signalling along mitogen-activated protein kinase pathways. Clin Exp Allergy 2004;34:1291-98
53. Newton R, Eddleston J, Haddad el-B, et al. Regulation of kinin receptors in airway epithelial cells by inflammatory cytokines and dexamethasone. Eur J Pharmacol 2002;441:193-202
54. Campos MM, de Souza GE, Ricci ND, Pesquero JL, Teixeira MM. Calixto JB. The role of migrating leukocytes in IL-1 beta-induced up-regulation of kinin B, receptors in rats. Br J Pharmacol 2002;135:1107-14
55. Morgan MM, Clayton CC, Heinricher MM. Simultaneous analysis of the time course for changes in core body temperature, activity, and nociception following systemic administration of interleukin-1 beta in the rat. Brain Res 2004;996:187-92
56. Schafers M, Marziniak M, Sorkin LS, Yaksh TL, Sommer C. Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Exp Neurol 2004;185:160-68
57. Dray A, Perkins MN. Kinins and pain. In: Farmer S, ed. The Kinin System. San Diego, CA: Academic Press, 1997:157-72
58. Aubel B, Kayser V, Mauborgne A, Farre A, Hamon M, Bourgoin S. Antihyperalgesic effects of cizolirtine in diabetic rats: Behavioral and biochemical studies. Pain 2004;110:22-3
59. Kamiya H, Zhang W, Sima AA. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004;56:827-35
60. 1 receptor antagonist B9858 inhibits a nociceptive spinal reflex in rabbits. Can J Physiol Pharmacol 2002;80:264-68